24/7 Market News Snapshot 10 April, 2025 – Pasithea Therapeutics Corp. Common Stock (NASDAQ:KTTA)

April 10, 2025

DENVER, Colo., 10 April, 2025 (www.247marketnews.com) – (NASDAQ:KTTA) are discussed in this article.
Pasithea Therapeutics Corp. (NASDAQ:KTTA) is experiencing a notable surge in its stock price, currently trading at $1.312, reflecting a substantial increase of 20.37% from the previous close of $1.090. The trading volume stands at an impressive 2.96 million shares, signaling strong investor confidence and market optimism surrounding the company’s innovative therapeutic pipeline. Investors are closely monitoring this bullish trend as Pasithea reinforces its position in the biotechnology sector.

In parallel, Pasithea has announced a critical advancement in its clinical research. The Phase 1 clinical trial of its candidate PAS-004 has gained momentum following a favorable review from an external Safety Review Committee, which has cleared the path for the company to proceed to Cohort 6, utilizing a 30mg capsule. This green light comes after observing positive safety data from three patients in the preceding Cohort 5, where no dose-limiting toxicities (DLTs) were reported. This finding is particularly significant given the history of rashes associated with competing MEK inhibitors, which typically lead to high discontinuation rates. In contrast, none of the first 19 participants in the PAS-004 trial experienced such adverse events, underscoring the candidate’s potential tolerance and feasibility.

Dr. Tiago Reis Marques, CEO of Pasithea, expressed enthusiasm over the encouraging response to patient enrollment for the next cohort. He emphasized the importance of maintaining effective pERK inhibition within established safety parameters as the trial progresses. The study, designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of PAS-004 in patients with advanced solid tumors driven by MAPK pathway mutations, positions Pasithea at the forefront of developing groundbreaking therapies for neurofibromatosis type 1 (NF1) and cancer. The company is set to provide further updates on safety metrics, pharmacokinetics, and pharmacodynamics in the coming weeks as it continues its mission to deliver compelling treatment options for patients in need.

Related news for (KTTA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.